<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190327043122N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-03-03</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Effect of Ondansetron on block of spinal anesthesia</public_title>
      <acronym></acronym>
      <scientific_title>Effect of  preoperative intravenous Ondansetron on level and time to regression of sensory and motor block in patients undergoing cesarean section  during spinal anesthesia</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-11-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>160</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/41160</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients is divided into two equal groups according to the table of random numbers (simple randomization) . In closed envelopes, syringes containing 2 cc of solution are provided by the anesthesiologist. Group A received  ondansetron and group B received normal saline , Blinding description: Since the drug form is the same in both groups and the injection method is the same, it is not possible for patients to identify the drug group in the operating room during surgery. The assessor and analyst will also be blinded of the groups. But the researcher that present during surgery will not be blind to the groups.</study_design>
      <phase>3</phase>
      <hc_freetext>Effect of ondansetron on level and time to regression of sensory and motor block in spinal anesthesia.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: 4 miligrames(2cc)  ondansetron (IV),15 minutes before spinal anesthesia  with 2.5 cc hyperbaric bupivacaine is administered. In the event of a  hypotension and bradicardia, more than 20% of the basal, 5-10 milligrames ephedrine and 0.5 to 1 mg atropine is injected , respectively. Intervention 2: Control group: 2cc  normal saline  (IV),15 minutes before spinal anesthesia  with 2.5 cc hyperbaric bupivacaine is administered. In the event of a  hypotension and bradicardia, more than 20% of the basal, 5-10 milligrames ephedrine and 0.5 to 1 mg atropine is injected , respectively.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Inforamations related to the primary outcomes

When:
Starting 6 months after publication

To whom:
ّFor people working in academic institutions and businesses

Conditions:
people working in academic institutions

Where to obtain:
Asgharisa@mums.ac.ir

How to obtain:
During 3-5 days

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Saleheh Asghari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shareeati Square, Qaem hospital</address>
        <city>mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9478791878</zip>
        <telephone>+98 51 3840 0000</telephone>
        <email>asgharisa@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Saleheh Asghari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shaaeeari Square, Qaem Hospital</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9176699199</zip>
        <telephone>+98 51 3840000</telephone>
        <email>asgharisa@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>women who candidate for cesarean section                          without any hearing problems                                                 , without neurologic disorders or                                                         use of alfa 2 agonists or calcium channel blockers in the last month                                                                                             Have not contraindication criteria for spinal anesthesia           Have not history of long QT in the patient and  family.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>45 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>need to general anesthesia</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>O74</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Complications of anesthesia during labor and delivery</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: 4 miligrames(2cc)  ondansetron (IV),15 minutes before spinal anesthesia  with 2.5 cc hyperbaric bupivacaine is administered. In the event of a  hypotension and bradicardia, more than 20% of the basal, 5-10 milligrames ephedrine and 0.5 to 1 mg atropine is injected , respectively.</i_keyword>
      <i_keyword>Control group: 2cc  normal saline  (IV),15 minutes before spinal anesthesia  with 2.5 cc hyperbaric bupivacaine is administered. In the event of a  hypotension and bradicardia, more than 20% of the basal, 5-10 milligrames ephedrine and 0.5 to 1 mg atropine is injected , respectively.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Level  and time to regression of sensory  block in spinal anesthesia. Timepoint: Every 2 minutes after spinal anesthesia until fixation of sensory level then every 30 minutes till regression of block to the level of S1. Method of measurement: blunt niddle.</prim_outcome>
      <prim_outcome>Time to reverse of motor block in spinal anesthesia. Timepoint: Every 30 minutes till regression of motor block. Method of measurement: Table of Modified Bromage scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Systolic blood pressure(SBP). Timepoint: Before and immediately after spinal anesthesia and every 3 minutes untill 30 minutes then every 5 minutes untill  the end of surgery. Method of measurement: Sphygmomanometer.</sec_outcome>
      <sec_outcome>Diastolic blood pressure(DBP). Timepoint: Before and immediately after spinal anesthesia and every 3 minutes untill 30 minutes then every 5 minutes untill  the end of surgery. Method of measurement: Sphygmomanometer.</sec_outcome>
      <sec_outcome>Mean arterial pressure(MAP). Timepoint: Before and immediately after spinal anesthesia and every 3 minutes untill 30 minutes then every 5 minutes untill  the end of surgery. Method of measurement: Sphygmomanometer.</sec_outcome>
      <sec_outcome>Heart rate(HR). Timepoint: Before and immediately after spinal anesthesia and every 3 minutes untill 30 minutes then every 5 minutes untill  the end of surgery. Method of measurement: Cardiac monitoring(5 leads).</sec_outcome>
      <sec_outcome>Pulse oximetry (SpO2). Timepoint: Before and immediately after spinal anesthesia and every 3 minutes untill 30 minutes then every 5 minutes untill  the end of surgery. Method of measurement: pulse oximetry.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-10-12</approval_date>
        <contact_name>Ethic committee of Mashhad University of Medical Sciences</contact_name>
        <contact_address>Shareeati Square , Qaem Hospital mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
